Usman Azam
Algemeen Directeur bij Inspirna, Inc.
Oorsprong van het eerstegraads netwerk van Usman Azam
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.
51
| Non-Profit Organization | Medical/Nursing Services | 51 |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA.
11
| Subsidiary | Miscellaneous Commercial Services | 11 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Usman Azam via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal Director/Board Member Director/Board Member Director/Board Member | |
| Stanford University | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Undergraduate Degree Doctorate Degree | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree Masters Business Admin Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| University of Illinois At Urbana–Champaign | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| New York University | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal President Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer President | |
| Baylor College of Medicine | College/University | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| BLUEBIRD BIO, INC. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| SHIRE | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer Director/Board Member | |
| Yale University | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing Corporate Officer/Principal | |
| INTELLIA THERAPEUTICS, INC. | Biotechnology | Chairman Founder Director of Finance/CFO | |
| University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Chief Executive Officer Founder Director/Board Member | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor Private Equity Investor | |
International Society for Cellular Therapy
 International Society for Cellular Therapy Miscellaneous Commercial ServicesCommercial Services International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal President | |
| University of Pennsylvania | College/University | Undergraduate Degree Director/Board Member Doctorate Degree | |
| Boston College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Weill Cornell Medical College | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor Corporate Officer/Principal | |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Investor Private Equity Analyst | |
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
| EDITAS MEDICINE, INC. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | General Counsel Public Communications Contact | |
| AMICUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
| XILIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Human Resources Officer | |
F-star Therapeutics Ltd.
 F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Imperial College London | College/University | Doctorate Degree Undergraduate Degree | |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Biotechnology | Director/Board Member Chief Executive Officer | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Chief Operating Officer | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| King's College London | College/University | Graduate Degree Doctorate Degree | |
| University College London | College/University | Doctorate Degree Corporate Officer/Principal | |
| TENAYA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| ATARA BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| PASSAGE BIO, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
BioXcel Corp.
 BioXcel Corp. Data Processing ServicesTechnology Services BioXcel Corp. is a biopharmaceutical company based in Branford, CT that utilizes advanced technologies such as AI to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel's AI-enabled platform, EvolverAI, helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process. The private company's family of companies includes BioXcel Therapeutics, Inc., which is a biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing AI and its approaches. BioXcel is deeply involved in creating breakthroughs in various categories of diseases. The company was founded by Vimal D. Mehta and Krishnan Nandabalan, with Vimal D. Mehta serving as the CEO since incorporation. | Data Processing Services | Director/Board Member Director/Board Member | |
| DNIB UNWIND INC | Biotechnology | Director/Board Member Director/Board Member | |
| ASTRIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Corporate Officer/Principal | |
Mnemo Therapeutics SAS
 Mnemo Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Mnemo Therapeutics SAS is a French biotechnology company that develops cell therapies to create accessible cures for cancer patients. The company is based in Paris, FR, and has subsidiaries in the United States. The company applies a novel approach to cell therapy using its enfinit platform, a groundbreaking drug discovery engine. Mnemo is committed to addressing the challenges in the field of immuno-oncology, such as a lack of cancer-specific targets, long-term persistence, and sensitivity. The company aims to engineer the future of immunotherapies to transform the lives of people with cancer by discovering novel cancer-specific targets and boosting immune activity to treat solid tumors. The company was founded in 2019 by Alain Maïore and Michel Sadelain. Robert LaCaze has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member Chairman |
Statistieken
Internationaal
| Verenigde Staten | 40 |
| Verenigd Koninkrijk | 8 |
| Frankrijk | 3 |
| Ierland | 2 |
| Canada | 2 |
Sectoraal
| Health Technology | 27 |
| Consumer Services | 18 |
| Commercial Services | 4 |
| Finance | 4 |
| Technology Services | 2 |
Operationeel
| Director/Board Member | 501 |
| Corporate Officer/Principal | 203 |
| Chief Executive Officer | 104 |
| Chairman | 97 |
| Independent Dir/Board Member | 89 |
Sterkste connecties
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Robin Smith | 46 |
| Jeffrey Leiden | 43 |
| Steven Paul | 39 |
| Perry Karsen | 38 |
| Eric Rowinsky | 36 |
| Nessan Bermingham | 36 |
| Dieter Weinand | 32 |
| Nancy T. Chang | 31 |
| Cynthia Collins | 27 |
| Nilesh Kumar | 26 |
| Mathieu Simon | 22 |
| Eduardo Bravo Fernández de Araoz | 19 |
| Jorge Conde | 18 |
| Sean Parker | 17 |
- Beurs
- Insiders
- Usman Azam
- Bedrijfsconnecties
